Clinical Trials in Pittsburgh

Showing 4861-4880 of 21,047 trials

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

NCT06832410

This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Type 1 DiabetesKidney Transplant

Vertex Pharmaceuticals Incorporated10 participantsStarted Mar 2025

Philadelphia, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States • Madison, Wisconsin, United States +4 more locations

RECRUITINGPhase 2115 miles

Study of JK07 in Patients With Chronic Heart Failure

NCT06369298

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.

Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction

Salubris Biotherapeutics Inc282 participantsStarted Mar 2024

Alexander City, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +59 more locations

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Study of JK07 in Patients With Chronic Heart Failure

Find Trials by Condition in Pittsburgh

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Sickle Cell Disease, Hemechip

CCT-102 or Expectant Management in Delayed Pregnancy Loss

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis

STICH3C Cardiac Magnetic Resonance Observational Study

Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Oral Contraceptive Pill (OCP) Pharmacogenomics

Families Left Behind

The ReTAVI Prospective Observational Registry